Research programme: antibody therapeutics - Kaketsuken/XOMA
Latest Information Update: 06 Nov 2018
At a glance
- Originator Kaketsuken; XOMA
- Class Antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Unspecified